The Efemoral Vascular Scaffold System (EVSS) for the Treatment of Patients With Symptomatic Peripheral Vascular Disease From Stenosis or Occlusion of the Femoropopliteal Artery

Peripheral Arterial Disease Clinical Trial

— Efemoral I  

Official title:

A Clinical Evaluation of the Efemoral Vascular Scaffold System (EVSS) for the Treatment of Patients With Symptomatic Peripheral Vascular Disease From Stenosis or Occlusion of the Femoropopliteal Artery

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04584632
• Other study ID #: CL05122020
• Status: Recruiting
• Phase: N/A
• Start date: September 22, 2020
• Est. completion date: April 2025

Study information

• Verified date: November 2023
• Source: Efemoral Medical, Inc.
• Contact: Lew Schwartz, MD
• Phone: 224-707-2601
• Email: lewis.schwartz[@]efemoralmedical.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To evaluate the safety and performance of the EVSS in patients with symptomatic peripheral vascular disease from stenosis or occlusion of the femoropopliteal artery

Description:

The EFEMORAL I study is a prospective, single-arm, open-labeled, multi-center, clinical investigation enrolling patients with arterial diameter of ≥5.5 mm and ≤6.5 mm and lesion length ≤90 mm receiving a single EVSS.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: April 2025
• Est. primary completion date: March 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Symptomatic peripheral vascular occlusive disease (Rutherford-Becker Clinical Category 2-4)

• Patient with life expectancy >36 months

• Females of childbearing potential must have negative pregnancy test

• Patient is able to provide informed consent

• Patient agrees to undergo all protocol-required follow-up examinations and requirements at the investigational site.

• Patient must be able to take antiplatelet and/or anticoagulant agents as prescribed

• Single de novo native disease segment of the superficial femoral artery (SFA) or P1 popliteal segment

• Reference vessel diameter =5.5 mm and =6.5 mm

• Target lesion length =90 mm

• Target lesion with =50% DS

• Inflow artery and popliteal artery free from flow-limiting lesion (DS <50%)

Exclusion Criteria:

• Hemoglobin <9.0 g/dL

• WBC <3,000 cells/mm3

• Platelet count <80,000 cells/mm3 or >700,000 cells/mm3

• Acute or chronic renal dysfunction with creatinine >2.5 mg/dl (176 µmol/L)

• Severe liver impairment as defined by total bilirubin =3 mg/dl or two times increase over the normal level of SGOT or SGPT

• A known hypersensitivity or contraindication to aspirin, heparin, bivalirudin, ticagrelor or sirolimus, or with contrast sensitivity for which the patient cannot be adequately pre-medicated

• Patient requires a planned procedure that would necessitate discontinuation of antiplatelet therapy

• Patient is unable to walk

• Patient has undergone a percutaneous vascular intervention <30 days prior to the planned index procedure

• Patient is maintained on chronic hemodialysis

• Patient has uncontrolled diabetes mellitus (HbA1c =7.0%).

• Patient has had a myocardial infarction within the previous 30 days of the planned index procedure

• Patient has had a stroke within the previous 30 days of the planned index procedure and/or has deficits from a prior stroke that limits the patient's ability to walk

• Patient has unstable angina defined as rest angina with ECG changes

• Patient has a local groin or acute systemic infection that has not been treated successfully or is currently under treatment

• Patient has acute thrombophlebitis, deep vein thrombosis or chronic venous insufficiency in either extremity

• Patient has other medical illnesses (e.g., cancer, congestive cardiomyopathy, etc.) that may cause the patient to be non-compliant with protocol requirements, confound the data interpretation or will prevent completion of all required follow up assessments through 36 months

• Patient is currently participating in an investigational drug, biologic, or device study that has not completed the primary endpoint or that clinically interferes with the current study endpoints

• Patient has ischemic or neuropathic ulcers on either foot

• Patient has undergone minor or major amputation of either lower extremity

• Patient is part of a vulnerable population who, in the judgment of the Investigator, is unable to give informed consent

• Target extremity with an angiographically significant (>50% DS) lesion located distal to the target lesion that requires treatment at the time of the index procedure or by a staged procedure

• Acute arterial ischemia of the target extremity

• Target extremity has been previously treated with open surgical revascularization (bypass or endarterectomy)

• Target vessel has been previously treated with stent, laser, atherectomy, surgical bypass, or endarterectomy

• Total occlusion (100% DS) of the ipsilateral inflow artery

• Angiographic evidence of thrombus in the target vessel

• The target lesion requires treatment with a device other than percutaneous transluminal balloon angioplasty (PTA) [e.g., orbital atherectomy, directional atherectomy, excimer laser, rotational atherectomy, cryoplasty, etc.]

• Target lesion is within or adjacent to an aneurysm

• Patient has angiographic evidence of thromboembolism or atheroembolism from treatment of an ipsilateral iliac lesion or from crossing or pre-dilating the target lesion

• Target lesion has moderate-to-severe calcification

• Target lesion with > 30% residual stenosis following pre-dilatation

Related Conditions & MeSH terms

• Constriction, Pathologic
• Femoropopliteal Stenosis
• Peripheral Arterial Disease
• Peripheral Vascular Diseases
• Stenosis
• Vascular Diseases

Intervention

Device:
• Efemoral Vascular Scaffold System (EVSS)
Balloon-expandable, bioresorbable vascular scaffolds coated with sirolimus

Locations

Country	Name	City	State
Australia	Prince Of Wales Hospital	Sydney
New Zealand	Auckland City Hospital	Auckland
New Zealand	Christchurch Hospital	Christchurch
New Zealand	Waikato Hospital	Hamilton

Sponsors (1)

Lead Sponsor	Collaborator
Efemoral Medical, Inc.

Countries where clinical trial is conducted

Australia,  New Zealand, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Target lesion percent mean diameter stenosis		Post procedure (Day 0) and 6 months
Other	Target lesion percent maximum diameter stenosis		post procedure (day 0) and at 6 months
Other	Target lesion late lumen loss		6 months
Other	Ischemia-driven target lesion revascularization (IDTLR)		1, 6, 12, 24 and 36 months
Other	Amputation (minor and major) of the target extremity		1, 6, 12, 24 and 36 months
Primary	Major Adverse Event (MAE)		30 days
Primary	Freedom from Binary Restenosis		12 months
Secondary	Device Success	Achievement of successful delivery and deployment of the study device(s) at the intended target lesion	Day 0
Secondary	Primary patency rate		1, 6, 12, 24 and 36 months
Secondary	Binary restenosis rate		1, 6, 12, 24 and 36 months
Secondary	Target lesion revascularization (TLR)		1, 6, 12, 24 and 36 months
Secondary	Ipsilateral extremity revascularization (IER)		1, 6, 12, 24 and 36 months
Secondary	Number of patients with Scaffold thrombosis		through 1 month
Secondary	Number of patients with scaffold occlusion		6, 12, 24 and 36 months
Secondary	Rate of Major Adverse Limb Events		through 36 months
Secondary	Ankle-brachial index (ABI) of target extremity		1, 6, 12, 24 and 36 months
Secondary	Limb salvage of target extremity		1, 6, 12, 24 and 36 months
Secondary	Rutherford-Becker Clinical Category for the target extremity		1, 6, 12, 24 and 36 months
Secondary	Walking impairment as assessed by Walking Impairment Questionnaire (WIQ)		1, 6, 12, 24 and 36 months
Secondary	Clinical Success	Attainment of a final residual stenosis of <30% using the study device(s) and/or any adjunctive device at the intended target lesion without complications	Up to 2 days after procedure
Secondary	Technical Success	Attainment of a final residual stenosis of <30% at the intended target lesion(	Day 0